Peer-reviewed publication in Cell Stem Cell unveils a novel differentiation process from Dr. Daleys lab to develop mature immune cells from induced pluripotent stem cells (iPSCs), a potentially disruptive advantage in the development of allogeneic iPSC-derived immunotherapies
New company to leverage ElevateBios unique iPSC platform and ecosystem of enabling technologies and manufacturing capabilities to create allogeneic immune cell therapies
First company to emerge from the previously announced five-year cell and gene therapy collaboration between Boston Childrens Hospital and ElevateBio
WALTHAM, Mass., August 04, 2022--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Childrens Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). This proprietary differentiation process overcomes the tendency of iPSCs to generate immature, embryonic blood cell types, and enables the generation of multiple subtypes of immune cells that display mature molecular signatures similar to T cells from adult blood. The peer-reviewed publication in the journal Cell Stem Cell showed that iPSC-derived mature T cells exhibited antitumor activity and cytokine secretion and could serve as an ideal source for the development of allogeneic "off-the-shelf" therapies.
This is the first company to emerge from the previously announced five-year collaboration between Boston Childrens Hospital and ElevateBio to accelerate the development of novel cell and gene therapies.
"At ElevateBio, we have been rapidly building fully integrated end-to-end cell and gene therapy enabling technologies and capabilities to enable the worlds most prolific scientific innovators and visionaries, such as Dr. Daley, to push the boundaries of the field and deliver powerful new therapeutic modalities for patients," said David Hallal, Chairman and CEO of ElevateBio. "This exciting new company is the first from our collaboration with Boston Childrens Hospital and is a prime example of how our integrated ecosystem our iPSC cell lines and process development capabilities, our gene editing technology, our CAR and TCR constructs, and our scale-up manufacturing capabilities creates the perfect foundation needed to turn these scientific breakthroughs into transformational medicines."
Story continues
"CAR-T therapies have revolutionized the treatment of certain blood cancers, with complete responses in many patients undergoing this type of treatment. However, current treatment strategies involve manufacturing a customized CAR-T cell product for each individual patient, which is cumbersome and labor-intensive," said Daley, senior author of the newly published Cell Stem Cell paper and whose lab is at Boston Childrens Hospital. "Our science offers an approach to circumvent these hurdles by offering an entirely new way of making allogeneic immune cell therapies that could pave the way for powerful treatments for a wide range of cancers."
Key findings shared in Cell Stem Cell publication: "EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity" (1):
A novel differentiation process discovered in Dr. George Daleys lab at Boston Childrens Hospital has been shown to promote definitive hematopoiesis and supports efficient production of mature T cells
This novel differentiation process incorporates repression of the histone methyltransferase EZH1 during iPSC differentiation to facilitate T cell maturation. The Daley lab showed previously that EZH1 is a negative regulator of lymphoid potential during embryonic blood development.
iPSC-T cells derived in a stroma-free, serum-free system following repression of EZH1, referred to as EZ-T cells, showed a molecular signature more closely resembling mature TCR T cells found in adult blood. Single cell RNA sequencing showed that activated EZ-T cells give rise to high levels of memory T cells, which promotes T cell longevity and may be essential for durable remissions in cancer patients.
In vitro studies showed EZ-T cells engineered to express anti-CD19 Chimeric Antigen Receptors (CARs) exhibited cytotoxic and cytokine-producing effector functions against CD19+ lymphoid tumor cells comparable to CAR-T cells engineered from adult blood.
In a xenograft mouse model injected with CD19+ diffuse large B-cell lymphoma (DLBCL) cells, EZ-T cells expressing anti-CD19 CARs demonstrated increased anti-tumor activity versus traditional iPSC-T cells generated without EZH1 knockdown.
(1) Jing, R., Scarfo, I., Daley, G., EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity, Cell Stem Cell, 2022
About ElevateBio:
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
For more information, visit us at http://www.elevate.bio, or follow Elevate on LinkedIn , Twitter, or Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005758/en/
Contacts
Investors: Catherine Huchu@elevate.bio
Media: Courtney HeathScientPRCourtney@scientpr.com
Read this article:
ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Childrens Hospital to Develop iPSC-Derived Allogeneic...
- Overcoming Tendonitis: How Stem Cell Treatments Are Revolutionizing Athlete Rehabilitation - Medical Tourism Magazine - February 21st, 2024
- Unproven Stem Cell Treatments Offer Hope & Risks - Healthline - January 4th, 2023
- Stem Cell or Bone Marrow Transplant Side Effects - American Cancer Society - November 24th, 2022
- Stem cell: $137 million buys more clinical trials, shared labs ... - November 24th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 29th, 2022
- What is a Bone Marrow Transplant (Stem Cell Transplant)? - Cancer.Net - October 29th, 2022
- Cameron Mathison Is Undergoing Stem Cell Treatments - October 4th, 2022
- Hiltzik: A judge undermines the FDA on stem cells - Los Angeles Times - October 4th, 2022
- Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD - GlobeNewswire - October 4th, 2022
- 15 Years of Heart - Newswise - October 4th, 2022
- QC Kinetix (The Heights) Helping Patients Heal Better from Joint Pain Through Houston Heights Sports Medicine - Yahoo Finance - October 4th, 2022
- Sources - Minnesota Timberwolves' Karl-Anthony Towns was on bed rest for days due to throat infection - ESPN - October 4th, 2022
- Innovative spaces and an expert team help Childrens Hospital New Orleans set the standard in cancer care - NOLA.com - September 25th, 2022
- Stem Cell Transplantation: What it Is, Process & Procedure - September 16th, 2022
- New stem cell therapy provides long-term brain protection against ALS - Study Finds - September 8th, 2022
- $150 Million Gift Takes Stem Cell Research to New Heights - University of California San Diego - September 8th, 2022
- Seattle biotech company is the first to receive approval to test B cell gene therapy in humans - GeekWire - September 8th, 2022
- Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia... - September 8th, 2022
- Could Stem-Cell Based Therapy Treat Type-1 Diabetes? A New Study Demonstrates the Treatments Potential - SciTechDaily - August 30th, 2022
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - GlobeNewswire - August 30th, 2022
- Global Cancer Stem Cells Market Estimated to Reach $1,722.7 Million by 2026 and Grow at 10.3% CAGR in the 2019 to 2026 Timeframe | [180-Pages] Report... - August 22nd, 2022
- Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society - August 14th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 14th, 2022
- Selma Blair 'Stopped Looking in the Mirror' After MS Treatments - TooFab - August 14th, 2022
- Stem Cells Are Needed To Treat Life-Threatening Diseases - Longevity LIVE - Longevity LIVE - July 19th, 2022
- Stem Cell Hair Transplant: What Is It and When Will It Be Available? - July 11th, 2022
- Stem cell treatments and regulation - a quick guide for consumers - July 11th, 2022
- Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace - Business Wire - July 3rd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - GlobeNewswire - June 22nd, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 22nd, 2022
- Sickle cell beta thalassemia: Causes, symptoms, and treatments - Medical News Today - June 22nd, 2022
- Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual... - June 22nd, 2022
- Six Things to Know About Stem Cell Treatment - HealthTechZone - May 15th, 2022
- CU Anschutz center for cell-based therapy gets $200 million expansion - The Denver Post - May 15th, 2022
- Differentiation therapy, Hox genes and Abemaciclib Research update 13th May - Brain Tumour Research - May 15th, 2022
- Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now - The Motley Fool - May 15th, 2022
- To help cope with the world's oldest population, Japan is investing in transplanted iPS stem cells - CBS News - April 19th, 2022
- Stem cell cure for lower back pain is all in the 'hiPS' - Study Finds - April 19th, 2022
- Versant-backed startup launches with plans to broaden cell therapy's reach - BioPharma Dive - April 19th, 2022
- CAR NK-Cell Therapy Is Quickly Growing in Immunotherapy - Targeted Oncology - April 19th, 2022
- Robert Vonderheide Appointed to Second Five-Year Term as Director of the Abramson Cancer Center - U Penn - April 19th, 2022
- Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer - DocWire News - April 19th, 2022
- Is Stem Cell Therapy Right for You? - Health Essentials from Cleveland Clinic - April 6th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - PR Newswire - April 6th, 2022
- Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says - AJMC.com Managed Markets Network - April 6th, 2022
- Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives - DocWire News - March 25th, 2022
- A Holistic Review on the Current and Future Status of Biology-Driven and Broad-Spectrum Therapeutic Options for Medulloblastoma - Cureus - March 25th, 2022
- Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL - AJMC.com Managed Markets Network - March 25th, 2022
- 'I wouldn't be here': Virginia girl, celebrating 11 years in remission, credits St. Jude with saving her life - News 3 WTKR Norfolk - March 25th, 2022
- This weird mouse with a tuft of human hair could be the future of a stem cell treatment for baldness - Boing Boing - January 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 20th, 2022
- How Stem Cell and Bone Marrow Transplants Are Used to ... - January 5th, 2022
- The Stem Cell Transplant Process - UChicago Medicine - January 5th, 2022
- Next Chapters: How Northern California blood recipients are doing years after donors helped save their lives - KCRA Sacramento - January 5th, 2022
- Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress - BarBend - January 5th, 2022
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent ... - KULR-TV - November 8th, 2021
- Managing superficial pyoderma with light therapy - DVM 360 - October 28th, 2021
- New Treatments and Tips for Dealing With Blood Cancer - Curetoday.com - October 28th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the - GlobeNewswire - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- FDA Warns About Stem Cell Therapies | FDA - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Kite's Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL - Clinical OMICs News - October 5th, 2021
- Prolymphocytic Leukemia: What Is It and How Is It Treated? - Healthline - August 31st, 2021
- Researchers Gaze into Space to Envision Future of Regenerative Medicine - UPMC & Pitt Health Sciences News Blog - UPMC - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive - August 18th, 2021
- A Third Dose of the COVID-19 Vaccine Recommended for Some Cancer Patients With Weakened Immune Systems - On Cancer - Memorial Sloan Kettering - August 18th, 2021
- Stem cells: What they are and what they do - Mayo Clinic - June 6th, 2021
- Stem Cell Therapy for Knee Pain: What Patients Should Know - June 6th, 2021
- Study clarifies the impact of getting old on hematopoietic stem cells - Microbioz India - December 26th, 2020
- Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial - Multiple Sclerosis News Today - December 22nd, 2020
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 22nd, 2020
- For Patients With HMA-Resistant MDS, What Are Their Options? - AJMC.com Managed Markets Network - December 22nd, 2020
- In COVID-19 Clinical Trials, Experts from Baptist Health's Cancer Institutes Treat Patients With Mild or Severe Symptoms - Baptist Health South... - December 22nd, 2020
- SPONSORED: 12 Charities of Christmas - Anthony Nolan - The Courier - December 22nd, 2020
- California's Proposition 14: short in the arm for stem cell research - BioNews - December 14th, 2020